A detailed history of Valley National Advisers Inc transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Valley National Advisers Inc holds 1,280 shares of REGN stock, worth $1 Million. This represents 0.24% of its overall portfolio holdings.

Number of Shares
1,280
Previous 1,448 11.6%
Holding current value
$1 Million
Previous $1.52 Million 11.63%
% of portfolio
0.24%
Previous 0.23%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

SELL
$1024.09 - $1201.76 $172,047 - $201,895
-168 Reduced 11.6%
1,280 $1.35 Million
Q2 2024

Jul 18, 2024

SELL
$883.2 - $1071.19 $4,416 - $5,355
-5 Reduced 0.34%
1,448 $1.52 Million
Q1 2024

Apr 19, 2024

BUY
$902.69 - $993.35 $53,258 - $58,607
59 Added 4.23%
1,453 $1.4 Million
Q4 2023

Jan 25, 2024

BUY
$775.18 - $881.7 $18,604 - $21,160
24 Added 1.75%
1,394 $1.22 Million
Q3 2023

Nov 13, 2023

BUY
$692.45 - $844.37 $23,543 - $28,708
34 Added 2.54%
1,370 $1.13 Million
Q2 2023

Jul 31, 2023

SELL
$700.03 - $830.35 $1,400 - $1,660
-2 Reduced 0.15%
1,336 $961,000
Q1 2023

Apr 26, 2023

SELL
$680.49 - $826.97 $9,526 - $11,577
-14 Reduced 1.04%
1,338 $1.07 Million
Q4 2022

Jan 12, 2023

SELL
$705.89 - $766.39 $9,176 - $9,963
-13 Reduced 0.95%
1,352 $959,000
Q3 2022

Nov 08, 2022

BUY
$573.97 - $724.32 $29,272 - $36,940
51 Added 3.88%
1,365 $986,000
Q2 2022

Jul 15, 2022

BUY
$548.35 - $738.84 $15,902 - $21,426
29 Added 2.26%
1,314 $798,000
Q1 2022

May 06, 2022

BUY
$595.12 - $698.43 $20,829 - $24,445
35 Added 2.8%
1,285 $898,000
Q4 2021

Feb 11, 2022

BUY
$543.48 - $670.97 $1,086 - $1,341
2 Added 0.16%
1,250 $789,000
Q3 2021

Nov 10, 2021

BUY
$574.03 - $680.96 $83,234 - $98,739
145 Added 13.15%
1,248 $755,000
Q2 2021

Aug 02, 2021

BUY
$472.8 - $558.54 $222,688 - $263,072
471 Added 74.53%
1,103 $616,000
Q1 2021

May 07, 2021

BUY
$446.73 - $548.2 $5,807 - $7,126
13 Added 2.1%
632 $299,000
Q4 2020

Feb 11, 2021

BUY
$478.3 - $607.98 $72,701 - $92,412
152 Added 32.55%
619 $299,000
Q3 2020

Nov 13, 2020

BUY
$544.75 - $658.21 $47,393 - $57,264
87 Added 22.89%
467 $261,000
Q2 2020

Aug 10, 2020

BUY
$493.32 - $643.92 $67,091 - $87,573
136 Added 55.74%
380 $237,000
Q1 2020

May 13, 2020

SELL
$336.18 - $494.43 $89,087 - $131,023
-265 Reduced 52.06%
244 $119,000
Q3 2019

Nov 12, 2019

BUY
$273.46 - $318.39 $2,734 - $3,183
10 Added 2.0%
509 $141,000
Q2 2019

Aug 08, 2019

BUY
$299.6 - $414.82 $47,636 - $65,956
159 Added 46.76%
499 $156,000
Q1 2019

Apr 26, 2019

SELL
$372.08 - $439.57 $59,160 - $69,891
-159 Reduced 31.86%
340 $140,000
Q4 2018

Feb 25, 2019

BUY
$335.82 - $403.04 $3,022 - $3,627
9 Added 1.84%
499 $186,000
Q2 2018

Aug 14, 2018

BUY
$284.6 - $344.99 $16,791 - $20,354
59 Added 13.69%
490 $169,000
Q1 2018

Apr 19, 2018

BUY
$315.82 - $393.78 $25,265 - $31,502
80 Added 22.79%
431 $148,000
Q4 2017

Feb 13, 2018

SELL
$358.63 - $469.95 $3,227 - $4,229
-9 Reduced 2.5%
351 $132,000
Q3 2017

Nov 14, 2017

BUY
$431.38 - $504.0 $155,296 - $181,440
360
360 $161,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $83.9B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Valley National Advisers Inc Portfolio

Follow Valley National Advisers Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Valley National Advisers Inc, based on Form 13F filings with the SEC.

News

Stay updated on Valley National Advisers Inc with notifications on news.